Amgen (AMGN) Said to Make $7B Bid for Human Genome (HGSI) in 2010

July 27, 2012 7:46 AM EDT Send to a Friend
Amgen (Nasdaq: AMGN) might be looking like a winner early, but that wasn't the case two years ago.

Current product portfolio notwithstanding, reports out today have Amgen making a $35 per share bid for Human Genome (Nasdaq: HGSI) back in August 2010. Despite the seemingly rich offer -- Human Genome's stock peaked at about $32.50 -- the $7 billion bid was rejected.

Today, Amgen is ticking higher following stronger-than-expected results for its second quarter, EPS of $1.83 beating views by 29 cents. Product sales rose 8 percent and its pipeline is in shipshape. In fact, shares are up a minimum of 44 percent since 2010, while Human Genome stock has fallen 56 percent over the same span.

Last week, Human Genome finally caved, agreeing to a $14.25 per share deal with GlaxoSmithKline (NYSE: GSK), which values the company at about $3 billion, or far less than what it would have received from Amgen.

Hindsight is 20/2, though. Human Genome had Benlysta in the works, which it hoped would propel the company to new heights. FDA approval in March 2011 led to paltry sales and a drop in Human Genome shares.

With the latest takeover, Human Genome invited Amgen to make a bid...but to no avail.

Amgen shares are about 4 percent higher in early trading, while Human Genome is flat.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Mergers and Acquisitions

Related Entities

Earnings

Add Your Comment